14 / 32
Dr David Straus discusses his abstract
picks fromASH 2016
David Straus, MD, is attending
physician on the Lymphoma Service
in the Department of Medicine at
Memorial Sloan-Kettering Cancer
Center in New York and contributor
to
PracticeUpdate Oncology
.
Plenary scientific session
Abstract 6:
Obinutuzumab-based induction
and maintenance prolongs progression-free
survival (PFS) in patients with previously
untreated follicular lymphoma: primary results
of the randomized phase 3 GALLIUM Study.
RE Marcus, AJ Davies, K Ando et al
This study included 1202 patients with
previously untreated follicular lymphoma
enrolled in GALLIUM, a global, open-
label, phase 3 study, who were randomised
to receive rituximab or obinutuzumab with
chemotherapy. After a median of 34.5 months
of follow-up, there was a 34% reduced risk
for progression or death in patients receiving
obinutuzumab compared with rituximab,
with 3-year INV-assessed PFS rates of 80%
and 73.3%, respectively. Patients receiving
obinutuzumab reported a higher frequency
of grade 3 to 5 AEs compared with patients
receiving rituximab (74.6% vs 67.8%);
however, fatal AE frequency was similar
between the two groups.
These results demonstrate a clinically
meaningful improvement with obinutuzumab-
based chemotherapy and maintenance,
suggesting a new standard of care for patients
with previously untreated follicular lymphoma.
Aggressive lymphoma (diffuse large
B-cell and other aggressive B-cell non-
Hodgkin lymphomas) – results from
prospective clinical trials
Abstract 469:
Phase III randomized study of
R-CHOP versus DA-EPOCH-R and molecular
analysis of untreated diffuse large B-cell
lymphoma: CALGB/Alliance 50303.
WH Wilson,
J sin-Ho, BN Pitcher, et al
This phase 3 study compared R-CHOP (arm
A) and DA-EPOCH-R (arm B) in patients
with recently diagnosed stage II or higher
DLBCL. Participants were at least 18 years
old and HIV-negative and were randomised
1:1 (n=524; 262 per arm) to receive the
interventions. Participants in arm B had more
grade 4 neutropenia (90% vs 56%), grade 4
thrombocytopenia (35% vs 6%), grade 3/4
febrile neutropenia (37% vs 19%), and grade
3 neuropathy (motor, 8% vs 1%; sensory, 15%
vs 3%). Both arms had similar grade 5 events.
There was no difference between the groups
on analysis of event-free survival (HR, 1.02;
RunWalk6 © ASH 2016
CONFERENCE COVERAGE
14
PRACTICEUPDATE HAEMATOLOGY & ONCOLOGY